132 related articles for article (PubMed ID: 32757024)
21. Semaphorin 3A in Ankylosing Spondylitis.
Liao HT; Lin YF; Chou CT; Tsai CY
J Microbiol Immunol Infect; 2019 Feb; 52(1):151-157. PubMed ID: 28736223
[TBL] [Abstract][Full Text] [Related]
22. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort.
Poddubnyy D; Haibel H; Braun J; Rudwaleit M; Sieper J
Arthritis Rheumatol; 2015 Sep; 67(9):2369-75. PubMed ID: 26017497
[TBL] [Abstract][Full Text] [Related]
23. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Kalstad S; Kvien TK
Rheumatology (Oxford); 2012 Aug; 51(8):1479-83. PubMed ID: 22499062
[TBL] [Abstract][Full Text] [Related]
24. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
[TBL] [Abstract][Full Text] [Related]
25. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.
Spoorenberg A; van der Heijde D; de Klerk E; Dougados M; de Vlam K; Mielants H; van der Tempel H; van der Linden S
J Rheumatol; 1999 Apr; 26(4):980-4. PubMed ID: 10229432
[TBL] [Abstract][Full Text] [Related]
26. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
Lukas C; Landewé R; Sieper J; Dougados M; Davis J; Braun J; van der Linden S; van der Heijde D;
Ann Rheum Dis; 2009 Jan; 68(1):18-24. PubMed ID: 18625618
[TBL] [Abstract][Full Text] [Related]
27. Gender difference in ASAS HI among patients with ankylosing spondylitis.
Chen HH; Chen YM; Lai KL; Hsieh TY; Hung WT; Lin CT; Tseng CW; Tang KT; Chou YY; Wu YD; Huang CY; Hsieh CW; Huang WN; Chen YH
PLoS One; 2020; 15(7):e0235678. PubMed ID: 32645080
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of clinical manifestations according to HLA-B(27) genotype in ankylosing spondylitis patients: real-world evidence from smart management system for spondyloarthritis].
Ji XJ; Sun K; Hu ZY; Zhang Y; Ma YP; Sun Z; Li KP; Zhu J; Zhang JL; Huang F
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):179-184. PubMed ID: 29518861
[No Abstract] [Full Text] [Related]
29. [A study on calculating the ankylosing spondylitis disease activity score according to the C-reactive protein level].
Ji X; Du J; Zhu J; Huang F; Zhang J
Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):206-10. PubMed ID: 26926373
[TBL] [Abstract][Full Text] [Related]
30. Comparison of ASDAS and BASDAI as a measure of disease activity in axial psoriatic arthritis.
Kılıç G; Kılıç E; Nas K; Karkucak M; Çapkın E; Dağlı AZ; Çevik R; Özgöçmen S
Clin Rheumatol; 2015 Mar; 34(3):515-21. PubMed ID: 24985042
[TBL] [Abstract][Full Text] [Related]
31. How to calculate the ASDAS based on C-reactive protein without individual questions from the BASDAI: the BASDAI-based ASDAS formula.
Aranda-Valera IC; Garrido-Castro JL; Ladehesa-Pineda L; Vazquez-Mellado J; Zarco P; Juanola X; Gonzalez-Navas C; Font-Ugalde P; Castro-Villegas MC
Rheumatology (Oxford); 2020 Jul; 59(7):1545-1549. PubMed ID: 31628804
[TBL] [Abstract][Full Text] [Related]
32. [The value of ankylosing spondylitis disease activity score in evaluating disease activity of ankylosing spondylitis].
DU XN; Li Y; Zhang SL; Zhu J; Huang F
Zhonghua Nei Ke Za Zhi; 2012 Mar; 51(3):206-9. PubMed ID: 22781894
[TBL] [Abstract][Full Text] [Related]
33. BASDAI cut-off values corresponding to ASDAS cut-off values.
Kwon OC; Park MC
Rheumatology (Oxford); 2022 May; 61(6):2369-2374. PubMed ID: 34558610
[TBL] [Abstract][Full Text] [Related]
34. Calculating the ankylosing spondylitis disease activity score if the conventional c-reactive protein level is below the limit of detection or if high-sensitivity c-reactive protein is used: an analysis in the DESIR cohort.
Machado P; Navarro-Compán V; Landewé R; van Gaalen FA; Roux C; van der Heijde D
Arthritis Rheumatol; 2015 Feb; 67(2):408-13. PubMed ID: 25332195
[TBL] [Abstract][Full Text] [Related]
35. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
36. Effective serum level of etanercept biosimilar and effect of antidrug antibodies on drug levels and clinical efficacy in Chinese patients with ankylosing spondylitis.
Dong Y; Li P; Xu T; Bi L
Clin Rheumatol; 2019 Jun; 38(6):1587-1594. PubMed ID: 30747393
[TBL] [Abstract][Full Text] [Related]
37. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.
Machado P; Landewé RB; Braun J; Baraliakos X; Hermann KG; Hsu B; Baker D; van der Heijde D
Ann Rheum Dis; 2012 Dec; 71(12):2002-5. PubMed ID: 22915615
[TBL] [Abstract][Full Text] [Related]
38. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
39. Routine Assessment of Patient Index Data (RAPID3) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Scores Yield Similar Information in 85 Korean Patients With Ankylosing Spondylitis Seen in Usual Clinical Care.
Park SH; Choe JY; Kim SK; Lee H; Castrejón I; Pincus T
J Clin Rheumatol; 2015 Sep; 21(6):300-4. PubMed ID: 26308349
[TBL] [Abstract][Full Text] [Related]
40. Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis.
Aydin SZ; Can M; Atagunduz P; Direskeneli H
Clin Exp Rheumatol; 2010; 28(5):752-5. PubMed ID: 20863448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
